00D
00H
00M
00S

Program

The ANZCHOG ASM 2025 program will include plenary sessions, invited speaker sessions, industry involvement and concurrent paper sessions.

Please find below a preliminary copy of the 2025 ASM program as a guide of what to expect. Please note the program is subject to changes.

The ASM program will now start on Wednesday afternoon, 30 July 2025 and conclude on Friday night, 1 August 2025

Day 1 – Wed 30 July
Day 2 – Thu 31 July
Day 3 – Fri 1 Aug

Time
0800-0900	Registration open Arrival tea and coffee
0900-1500	ANZCHOG Pre-Conference Nurses Workshop	ANZCHOG Pre-Conference Education Day: Holistic Patient and Family Care from Diagnosis to Survivorship	ANZCHOG Paediatric Oncology Fellows Day (Offsite)
1500-1600	Afternoon Tea – Registration Open, Trade Display and Poster Viewing
1600-1630	Opening Ceremony
1630-1715	Plenary 1 – Early Phase Trials Can we cure all children of cancer without harm? Dr Quentin Campbell-Hewson, RVI Newcastle-upon-Tyne, UK
1715-1800	Plenary 2 – TBC
1800-1915	Welcome Reception in Exhibition
1930-2130	Partner Dinner Symposium
1930-2130	Sponsored by Jazz Pharmaceuticals

Key for Program

Time
0730-0830	.partnership-50-2025
0800-0900	.break-50-2025
1345-1515	.subheader2025
1345-1515	[Placeholder]

Time
0730-0830	Breakfast Symposium 1
0800-0900	Registration open Arrival tea and coffee
0900-0945	Plenary 3 – Gene Therapy and HSCT
0945-1030	Plenary 4 – Neuropsychology Network neuroscience and brain repair in children with pediatric brain tumours. Dr Donald Mabbott, SickKids Involvement made possible by Robert Connor Dawes Foundation
1030-1100	Morning Tea – Trade Display and Poster Viewing
1100-1145	Plenary 5 – Neuroblastoma
1145-1230	Plenary 6 – Australian Trials on an International Stage A/ Prof Peter Grimison, Chris O’Brien Lifehouse
1230-1345	Lunch – Trade Display and Poster Viewing
	Partner Lunch Symposium
	Sponsored by Alexion
1345-1515	ANZCHOG Clinical Trials Update
1515-1545	Afternoon Tea – Trade Display and Poster Viewing
1545-1615	Meet the Expert Session 1	Meet the Expert Session 2	Meet the Expert Session 3
1545-1615	Brought to you by Recordati Rare Diseases
1630-1800	Concurrent 1 – Neuro-Oncology	Concurrent 2 – Adolescent and Young Adult/b>	Concurrent 3 – Optimising Patient Experience
	Driving CARs into DMG Prof David Ziegler, Sydney Children’s Hospital Involvement made possible by RUNDIPG	P3BeP A/Prof Peter Grimison, Chris O’Brien Lifehouse	Can we go home now? QPPHON enables care as close to home as possible Jessica Nicholson, Children’s Health Queensland
		A Review of the Diagnosis, Treatment and Outcomes for Adolescents and Young Adults with Gonadal Germ Cell Tumours in Queensland from 2017 to 2022 Rick Walker, Queensland Children’s Hospital	Improving the child cancer experience for New Zealand families: A qualitative study Anna Timmings, Te Whatu Ora – Lakes
	DNA Damage Response Inhibitors Enhance the Efficacy of Radiation in Preclinical Models of Medulloblastoma Meegan Howlett, The Kids Institute Australia	Enhancing Australian AYA Psychosocial Care: Updated Guidelines and State of the Literature Ursula Sansom-Daly, University of New South Wales	Top Ten Research Priorities for Cancer in Children and Young People in Australia Gayani De Silva, Queensland University of Technology
	Body Composition Changes in Early Survivors of Childhood Brain Tumours: Data from the CARaB C Study Erin Sharwood, Children’s Health Queensland	Evaluating Distress Scores and Unmet Needs in Adolescents and Young Adults with Cancer Undergoing Treatment or as Survivors in a Large Australian Paediatric and Adult Health Service Tegan Dunmall, Monash Health	Session information coming soon
	Radiological, Histopathological and Molecular Features of Gliomas in Li Fraumeni Syndrome Noemi Fuentes Bolano, Sydney Children’s Hospital and Children’s Cancer Institute	Optimising Intravenous Nutrition in Paediatric Cancer Care: Insights from New Zealand’s Leading Tertiary Centre Amy Lovell, The University of Auckland and Starship Blood and Cancer Centre	Building resilience: Workforce strategies to combat distress and burnout in Australian children’s cancer nurses Natalie Bradford, Queensland University of Technology
	Launch of the Australian Family Handbook for Childhood Brain Tumour Melanie Rolfe, Queensland University of Technology	Identification of molecular prognostic and therapy resistance signatures in childhood and AYA osteosarcomas Nataliya Zhukova, Hudson Institute of Medical Research	What do First Nations Communities Need From Childhood Cancer Research? Jessica Buck, The Kids Research Institute
1800 -1915	ANZCHOG 2025 ASM Poster Session in Exhibition

Time
0730-0830	.partnership-50-2025
0800-0900	.break-50-2025
1345-1515	.subheader2025
1345-1515	[Placeholder]

Key for Program

Time
0730-0830	Breakfast Symposium 2
0730-0830	Sponsored by Bayer
0800-0900	Registration open Arrival tea and coffee
0900-0945	Plenary 7 – Transplant
0945-1030	Plenary 8 – Nausea and Vomiting Prof Lee Dupuis, SickKids
1030-1100	Morning Tea – Trade Display and Poster Viewing
1100-1230	Concurrent 4 – Precision Medicine	Concurrent 5 – Equitable World Health	Concurrent 6 – Haematology
	Mapping Proteomic Differences between High-Risk and Non-High-Risk Neuroblastoma Urwah Nawaz, Children’s Medical Research Institute	Strengthening Paediatric Cancer and Palliative Care Capacity in Papua New Guinea Dr Gwenda Anga, Port Moresby General Hospital Involvement made possible by QUT Palliative Care
	Quality of life, distress and support needs of families of children with high-risk sarcoma enrolled in a precision medicine trial Brittany McGill, University New South Wales
	The STAMP Inhibitor asciminib is a Novel Therapy for ABL1-rearranged ALL Laura Eadie, South Australian Health and Medical Research Institute
	Thematic analysis of the key factors that guide oncologist decisions to use precision-guided treatment in paediatric cancer Xian Zou, University New South Wales	Current Incidence And Outcome Of Childhood Cancer In Fiji: A Baseline For The Global Initiative For Childhood Cancer Siobhan Cross, Health NZ	Expanding the Aplastic Anaemia and Other Bone Marrow Failure Registry (AAR) to New Zealand – Exploring epidemiology, availability of diagnostic testing, and genomic profiles Nathanael Lucas, Monash University and The University of Otago
	PREDICT and Validate: Decoding the Genome of Childhood Cancer Predisposition Safaa Al Haj Hussein, Children’s Hospital at Westmead	Childhood Cancer Survival in Australia: A population-based analysis of prognostic indicators and survival disparities by geography and socio-economic status Natalie Bradford, Queensland University of Technology	What Should We Research? Defining Priorities for Paediatric Haematopoietic Stem Cell Transplant (HSCT) Through Stakeholder Engagement Roxanne Dyas, Murdoch Childrens Research Institute
	Derivation of a Proteomic Signature for Prediction of Relapse in Paediatric Acute Lymphoblastic Leukaemia Veronica Yeung, Children’s Medical Research Institute	Quantifying the social and economic burden of childhood cancer on New Zealand families and the impact of location, ethnicity and cancer type Anna Timmings, Te Whatu Ora – Lakes
1230-1345	Lunch – Trade Display and Poster Viewing
	Partner Lunch Symposium
	Sponsored by Norgine
1345-1515	Concurrent 7 – Solid Tumours	Concurrent 8 – Supportive Cares and Treatments	Concurrent 9 – Leukaemia/ Lymphoma
	SMARCB1 and rhabdoid tumours: germline versus acquired pathogenic variants Noemi Fuentes Bolano, Sydney Children’s Hospital and Children’s Cancer Institute		Antibiotic-Induced Ablation of Gut Microbiota in Murine Models of Acute Lymphoblastic Leukaemia Results in Variable Patterns of Leukaemic Cell Engraftment Cate Cheney, South Australian Health and Medical Research Institute
	Variations of rotationplasty surgical techniques and implications for physiotherapy in four children at the Queensland Children’s Hospital Elise Mosey, Children’s Health Queensland	Elevated plasma CXCL9 and CHI3L1 prior to haematopoietic stem cell transplant predict post transplant lung complications in children Hannah Walker, The Royal Children’s Hospital	Addressing caregiver unmet information needs at end-of treatment for acute lymphoblastic leukaemia: The Emerge Program Cinzia De Luca, Children’s Cancer Centre
	New combinations for HR-NB through systematic drug screening and rational targeting of relapse pathways in clinical trial-like PDX studies Brandon Hearn, Children’s Cancer Institute	Pharmacogenomics in Paediatric Oncology: Australian Patient and Caregiver Perspectives Claire Moore, Murdoch Children’s Research Institute	Next generation sequencing (NGS) for detection and monitoring of minimal residual disease in acute lymphoblastic leukaemia Nicola Mason, The Children’s Hospital at Westmead
	Defining mechanisms of cisplatin resistance in osteosarcoma using a whole genome CRISPR activation screen Elise Young, Monash Health and Hudson Institute	Y-Site Compatibility of Ketamine with Other Commonly Administered Drugs in Pediatric Oncology Johnathan Soggee, Perth Children’s Hospital	Acquired copy number variants are highly correlated with Ph+ALL subgroups identified by transcriptomic analysis Jacqueline Rehnme, South Australian Health and Medical Research Institute
	Journey mapping of paediatric patients with orthopaedic sarcoma: challenges and support needs identified Caitlin Smith, Perth Children’s Hospital	Clinical characterisation and early intervention for the physically vulnerable child with cancer: protocol for a mixed-methods pilot RCT Sarah Grimshaw, Murdoch Children’s Research Institute	Acquired copy number variants are highly correlated with Ph+ALL subgroups identified by transcriptomic analysis Jacqueline Rehn, South Australian Health and Medical Research Institute
	Concurrent Langerhans Cell Histiocytosis and Ganglioneuroblastoma with a BRAF V600E mutation Jiann Pazhamlil, Queensland Children’s Hospital	A Surveillance Study in Multi-Organ Cancer Predisposition Syndromes in Paediatrics (SMOC Junior): Preliminary Results Noemi Fuentes Bolanos, Sydney Children’s Hospital and Children’s Cancer Institute	Prioritising equitable outcomes for children and young people with cancer: Using the He Pikinga Wairoa Implementation Framework to co-design a prehabilitation intervention in Aotearoa, New Zealand Alexis Ross, University of Auckland
1515-1545	Afternoon Tea – Trade Display and Poster Viewing
1545-1630	Plenary 9 – Haematology Emerging therapies in inherited bleeding disorders Dr Jane Mason, Royal Brisbane and Women’s Hospital
1630-1745	ANZCHOG 2025 ASM Best Abstracts Queensland Youth Cancer Service: Prioritising Adolescent and Young Adult futures through connection and wrap around care Tracy Till, Queensland Children’s Hospital Potential for Pharmacogenomics to Improve Medication Safety and Efficacy in Australian Paediatric Oncology Patients Claire Moore, Murdoch Children’s Research Institute Using Methylation Array Profiling for Juvenile Myelomonocytic Leukaemia Classification Christine White, Victorian Clinical Genetics Services Exploring Symptom Burden and Symptom Clusters in Childhood and Adolescent Cancer Survivors: A Multi-perspective Cross-sectional Study Sarah Ellis, University New South Wales Towards a National System for Minimally Invasive Monitoring of any Childhood Cancer: Lessons Learnt and Opportunities for Impact Rob Salomon, Children’s Cancer Institute
1900-0000	Gala Dinner
1900-0000	Venue: Brisbane City Hall Dress code: Cocktail Information: An elegant evening of celebration featuring a three course dinner, drinks, and the abstract awards. Set in one of the city’s most iconic venues, this special night offers the perfect opportunity to connect with colleagues and honour excellence in our field.

Key for Program

Time
0730-0830	.partnership-50-2025
0800-0900	.break-50-2025
1345-1515	.subheader2025
1345-1515	[Placeholder]

Key dates

About

Organiser

MCI Australia
3A, Level 3, 200 Creek Street
Spring Hill, QLD 4000

Join our mailing list to stay updated.

Join our mailing list to stay updated.

Privacy Policy | Designed and built by MCI Australia

© 2021-2025 ASM. All rights reserved.

About

Program

Partners

Organiser

MCI Australia
Level 11, 87 Wickham Terrace
Spring Hill QLD 4000

P: +61 7 3858 5400

E: info@asm-anzchog.com

Privacy Policy | Designed and built by MCI Australia

© 2021-2025 ASM. All rights reserved.

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
.ASPXANONYMOUS	12 hours	This cookies is set by ASP.NET and is used to track users within a session without requiring the user to log in.
ARRAffinity	session	ARRAffinity cookie is set by Azure app service, and allows the service to choose the right instance established by a user to deliver subsequent requests made by that user.
ARRAffinitySameSite	session	This cookie is set by Windows Azure cloud, and is used for load balancing to make sure the visitor page requests are routed to the same server in any browsing session.
cookielawinfo-checkbox-advertisement	session	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	session	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
elementor	never	This cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_CXDS3XEJ90	2 years	This cookie is installed by Google Analytics.
_gat_gtag_UA_188778553_3	1 minute	Set by Google to distinguish users.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.

Others